These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23266403)

  • 21. New frontiers in fibrotic disease therapies: The focus of the Joan and Joel Rosenbloom Center for Fibrotic Diseases at Thomas Jefferson University.
    Rosenbloom J; Ren S; Macarak E
    Matrix Biol; 2016 Apr; 51():14-25. PubMed ID: 26807756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Liver fibrosis and cirrhosis--selected cytokines, growth factors and proteins. Part II].
    Wirkowska A; Paczek L
    Przegl Lek; 2011; 68(4):228-30. PubMed ID: 21853679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis.
    Dobie R; Henderson NC
    F1000Res; 2016; 5():. PubMed ID: 27508067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease.
    Gomez IG; Roach AM; Nakagawa N; Amatucci A; Johnson BG; Dunn K; Kelly MC; Karaca G; Zheng TS; Szak S; Peppiatt-Wildman CM; Burkly LC; Duffield JS
    J Am Soc Nephrol; 2016 Dec; 27(12):3639-3652. PubMed ID: 27026366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of myofibroblast differentiation: a review.
    Yang X; Chen B; Liu T; Chen X
    Eur J Pharmacol; 2014 Jul; 734():83-90. PubMed ID: 24742377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myofibroblasts and lung fibrosis induced by carbon nanotube exposure.
    Dong J; Ma Q
    Part Fibre Toxicol; 2016 Nov; 13(1):60. PubMed ID: 27814727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-fibrotic treatments: A review of clinical evidence.
    Allinovi M; De Chiara L; Angelotti ML; Becherucci F; Romagnani P
    Matrix Biol; 2018 Aug; 68-69():333-354. PubMed ID: 29654884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?
    Dees C; Distler JH
    Exp Dermatol; 2013 Nov; 22(11):710-3. PubMed ID: 24118232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epigenetic feedback loop between DNA methylation and microRNAs in fibrotic disease with an emphasis on DNA methyltransferases.
    Sun X; He Y; Huang C; Ma TT; Li J
    Cell Signal; 2013 Sep; 25(9):1870-6. PubMed ID: 23707521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
    Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
    Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pro-fibrotic properties of transforming growth factor on human fibroblasts are counteracted by caffeic acid by inhibiting myofibroblast formation and collagen synthesis.
    Mia MM; Bank RA
    Cell Tissue Res; 2016 Mar; 363(3):775-89. PubMed ID: 26453399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin-mediated regulation of TGFβ in fibrosis.
    Henderson NC; Sheppard D
    Biochim Biophys Acta; 2013 Jul; 1832(7):891-6. PubMed ID: 23046811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Developments on the Treatment of Liver Fibrosis.
    Koyama Y; Xu J; Liu X; Brenner DA
    Dig Dis; 2016; 34(5):589-96. PubMed ID: 27332862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases.
    Schwalm S; Pfeilschifter J; Huwiler A
    Biochim Biophys Acta; 2013 Jan; 1831(1):239-50. PubMed ID: 22889995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow contributions to fibrosis.
    Mackinnon A; Forbes S
    Biochim Biophys Acta; 2013 Jul; 1832(7):955-61. PubMed ID: 23385196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition.
    Guarino M; Tosoni A; Nebuloni M
    Hum Pathol; 2009 Oct; 40(10):1365-76. PubMed ID: 19695676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy.
    Castelino FV; Varga J
    Curr Opin Rheumatol; 2014 Nov; 26(6):607-14. PubMed ID: 25191991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic Regulation of Myofibroblast Phenotypes in Fibrosis.
    Duong TE; Hagood JS
    Curr Pathobiol Rep; 2018 Mar; 6(1):79-96. PubMed ID: 30271681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?
    Muñoz-Félix JM; González-Núñez M; Martínez-Salgado C; López-Novoa JM
    Pharmacol Ther; 2015 Dec; 156():44-58. PubMed ID: 26493350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.